Regulus HCV Candidate On Clinical Hold After Second Jaundice Report
This article was originally published in The Pink Sheet Daily
First jaundice adverse event was deemed unlikely to be connected to treatment with RG-101, and the second patient presents similar profile of overall health and co-morbidities.
You may also be interested in...
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Execs On The Move: Medical Microinstruments Gets New CEO; Changes At iRhythm; Aethlon Makes A Promotion
Corindus Vascular Robotics CEO made a lateral move to Medical Microinstruments; iRhythm hires a new CEO, while the former CEO stays on as a director; Aethlon promotes a director to chief business officer; and more.